A campaign to improve lives and accelerate cures
We did it! (October 7, 2021 update)
Exciting news: We’ve recently crossed the finish line for the ALL IN campaign. This collective achievement is the product of contributions from more than six thousand families and organizations around the world. We're so grateful! Learn more about the accomplishments ALL IN made possible — and the exciting opportunities now on the horizon — right this way.
For the first time, there is now a credible path to making chordoma a manageable disease — to treatments that don’t just slow the disease down, but that have a real chance of enabling patients to get on with their lives. With adequate investment, these treatments are years, not decades away.
This is a profoundly significant opportunity for everyone whose life has been disrupted by chordoma. And it’s an opportunity that doesn’t come along often in the world of oncology.
So what do you do when an opportunity like this emerges? You seize the moment. You swing for the fences. You go all in.
ALL IN is our rallying cry. $16M is our goal.
A confluence of recent advances have created unprecedented opportunities to deliver the first effective treatments to chordoma patients in our lifetime.
Realizing these opportunities will require at least $16M.
Through strategic investments and partnerships, these funds will enable us to leverage even greater resources from other entities including companies, foundations and government funding agencies.
$12M RESEARCH to advance the first brachyury drugs into the clinic, apply immunotherapy advances to chordoma, and systematically identify existing drugs that could help in the near term.
$2M HEALTHCARE IMPROVEMENT to enable treatment informed by the medical journey of every patient.
$2M PATIENT SERVICES to create a better experience for all affected.
In addition to being the Achilles' heel of chordoma, brachyury is also implicated in progression, metastasis, and resistance to therapy in many other cancers — including breast, lung, colon, and prostate cancers. Hence, investments in brachyury drug discovery will yield new treatments that are likely to have an impact far beyond chordoma.
Special thanks to our campaign committee members for their leadership and generosity.
Joel Beckman, Chair